Eye implant offers new hope

Article

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

A new implant that allows patients suffering from advanced age-related macular degeneration (AMD) to improve their general vision and regain independence is now being implanted in the UK.

The CentraSight treatment programme features a small telescope implant for patients with binocular end stage AMD. This treatment has, until now, only been available in the US and is the only surgical option that has been clinically proven to improve visual quality and quality in life for patients at this stage of the disease.

Mr Ahmed El-Amir, consultant ophthalmologist at Spire Dunedin, Reading, UK, was the first surgeon to perform the procedure in the UK. “I am very pleased to be able to offer my patients this revolutionary treatment, which is a true paradigm shift for patients with untreatable, advanced AMD who have had, up to now, very limited options in improving their quality of life,” he said.

Another surgeon who has recently performed a CentraSight procedure, Mr Nick Wilson-Holt (Duchy Hospital, Truro, UK) added, “CentraSight is a clinical programme that is very carefully targeted only to suitable patients who will potentially gain visual acuity from the procedure. It is not a cure for end-stage AMD, but it allows patients to use the undamaged part of their central retina to be able to see or discern objects using portions of their central vision once more.”

More detailed information about the procedure and its availability may be found on the website.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.